Centient Biotech Investor submits: CuraGen (CRGN) sold its majority-owned 454 Life Sciences division to Roche (RHHBY) for $155 million. Roche Diagnostics has been the worldwide distributor of the Genome Sequencer systems produced by 454. Of the $155 purchase price, $140 million will be paid in cash, and another $14.9 million will come from the exercise of stock options. >>> Discuss This Story
